I agree with your perspective that DCVax has significant potential to save lives, but Northwest Biotherapeutics (NWBO) is progressing far too slowly.
The company’s sluggish pace, particularly in securing Marketing Authorization Application (MAA) approval, is frustrating for investors and patients alike.
NWBO’s stock price, languishing at $0.23, reflects this lack of momentum.
A key issue appears to be the leadership of CEO Linda Powers. If a more dynamic and effective CEO were at the helm, it’s reasonable to question whether NWBO would still be stuck in this prolonged waiting period for MAA approval. Strong leadership drives results, and the current pace suggests a lack of urgency or strategic focus.
When LP stated, “Go big or go home,” it implied ambition.
However, her actions seem more aligned with personal gain than delivering value to retail investors or advancing DCVax to market.
With her reported ownership of hundreds of millions of NWBO shares, her financial incentives may not align with those of smaller shareholders.
This perception is compounded by the company’s history: nine years ago when I started investing here, NWBO had fewer than 100 million outstanding shares, but dilution and slow progress have eroded investor confidence.
In short, while DCVax holds immense promise, NWBO’s leadership under LP appears to prioritize personal interests over the urgent needs of patients and investors.
A change in leadership could potentially accelerate progress and restore trust, but it's not going to happen in near future and we are stuck here with not-so-competent like CEO.
Market Data 
Markets 
